Skip to main navigation Skip to search Skip to main content

First- versus Third-Generation EGFR Tyrosine Kinase Inhibitors in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalCancers
Volume15
StatePublished - Apr 20 2023

Cite this